1. Scrip
  2. >>Business
  3. >>Financing

Zai Lab Soars On Nasdaq Debut

 
• By Brian Yang

Shanghai-based drug developer Zai Lab shares jumped on its first day of public trading, reflecting the strong interest in drug development in China.

Money Wave
money wave • Source: Shutterstock

Shanghai-based drug developer Zai Lab shares surged $9.93 (55%) to $27.93 on its first day of trading. Through an initial public offering on Nasdaq, the company issued 8.3m American Depository Shares (ADS) at $18 each to raise $150m. Reflecting the strong interest in Chinese drug development, the offering was increased from the previously planned $100m offering.

Founded in 2013 by serial entrepreneur Samantha Du, Shanghai Zai Lab Ltd. is now a rising star among new...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

Finance Watch: Scorpion Spinout Antares Launches With $177m For Precision Medicines

 
• By Mandy Jackson

Private Company Edition: Antares’ lead asset will enter the clinic in 2026 after Lilly committed up to $2.5bn for Scorpion’s Phase I/II PI3Kα inhibitor STX-478. Also, Amplify raised $200m for its first biotech VC fund and Mosanna raised an $80m series A round, among other financings.